...
首页> 外文期刊>International Journal of Clinical and Experimental Pathology >Reversibility of Aberrant Global DNA and Estrogen Receptor-α Gene Methylation Distinguishes Colorectal Precancer from Cancer
【24h】

Reversibility of Aberrant Global DNA and Estrogen Receptor-α Gene Methylation Distinguishes Colorectal Precancer from Cancer

机译:异常的全球DNA和雌激素受体-α基因甲基化的可逆性区分大肠癌从癌症。

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Alterations in the global methylation of DNA and in specific regulatory genes are two epigenetic alterations found in cancer. However, the significance of epigenetic changes for diagnosis and/or prognosis of colorectal cancer have not been established, although it has been extensively investigated. Recently we have identified a new type of cancer cell called precancerous stem cells (pCSCs) and proposed that cancer may arise from a lengthy development process of tumor initiating cells (TICs) → pCSCs → cancer stem cells (CSCs) → cancer, which is in parallel to histological changes of hyperplasia (TICs) → precancer (pCSCs) → carcinoma (CSCs/cancer cells), accompanied by clonal evolutionary epigenetic and genetic alterations. In this study, we investigated whether aberrant DNA methylation can be used as a biomarker for the differentiation between premalignant and malignant lesions in the colorectum. The profile of global DNA and estrogen receptor (ER)-α gene methylation during cancer development was determined by analysis of 5-methylcytosine (5-MeC) using immunohistochemical (IHC) staining, dot blot analysis or a quantitative gene methylation assay (QGMA). Herein we show that global DNA hypomethylation and ER-α gene hypermethylation are progressively enhanced from hyperplastic polyps (HPs) → adenomatous polyps (APs) → adenomatous carcinoma (AdCa). The aberrant methylation can be completely reversed in APs, but not in AdCa by a nonsteroidal anti-inflammatory drug (NSAID) celecoxib, which is a selective inhibitor of cyclooxygenase-2 (Cox-2), suggesting that the epigenetic alterations between colorectal precancer (AP) and cancer (AdCa) are fundamentally different in response to anti-cancer therapy. In normal colorectal mucosa, while global DNA methylation was not affected by aging, ER-α gene methylation was significantly increased with aging. However, this increase did not reach the level observed in colorectal APs. Taken together, reversibility of aberrant global DNA and ER-α gene methylation distinguishes colorectal precancer from cancer.
机译:DNA整体甲基化和特定调控基因的改变是在癌症中发现的两种表观遗传改变。然而,尽管已经对其进行了广泛的研究,但表观遗传学改变对于大肠癌的诊断和/或预后的重要性尚未确立。最近,我们已经鉴定出一种新型的癌细胞,称为癌前干细胞(pCSCs),并提出癌症可能源于肿瘤起始细胞(TICs)漫长的发展过程。 pCSC→癌症干细胞(CSC)→与组织增生(TICs)的组织学变化平行的癌症前癌(pCSC)→癌(CSC /癌细胞),并伴有克隆进化表观遗传和遗传改变。在这项研究中,我们调查了异常的DNA甲基化是否可以用作区分结肠直肠癌前病变和恶性病变的生物标记。全球DNA和雌激素受体(ER)的概况-α通过使用免疫组化(IHC)染色,斑点印迹分析或定量基因甲基化测定(QGMA)对5-甲基胞嘧啶(5-MeC)进行分析,确定癌症发展过程中的基因甲基化。本文中,我们显示了总体DNA低甲基化和ER-α增生性息肉(HPs)逐渐增强了基因的高甲基化作用→腺瘤性息肉(AP)→腺瘤癌(AdCa)。非甾体抗炎药(NSAID)celecoxib可以完全逆转AP中的异常甲基化,但不能完全逆转AdCa中的异常甲基化,这是一种选择性的环氧合酶2(Cox-2)抑制剂,表明结直肠癌前体之间的表观遗传改变( AP)和癌症(AdCa)在抗癌治疗方面有根本不同。在正常的大肠粘膜中,虽然总体DNA甲基化不受衰老影响,但ER-α随着年龄的增长,基因甲基化显着增加。然而,这种增加没有达到在结直肠AP中观察到的水平。总体而言,异常的全球DNA和ER-α的可逆性基因甲基化将大肠癌与癌症区分开来。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号